Literature DB >> 2911665

Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging.

R S Nyman1, S M Rehn, B L Glimelius, H E Hagberg, A L Hemmingsson, C J Sundström.   

Abstract

Eighteen patients with mediastinal involvement of Hodgkin disease were examined with magnetic resonance (MR) imaging before and during therapy to find out if size of residual masses could be predicted from the MR characteristics of the tumor at diagnosis. After the first treatment, a significant decrease in T2 values and signal intensity ratios of tumor to fat and tumor to muscle was found in all patients. There was no significant change in T1 values. The relative decrease in tumor size correlated well with signal intensity ratios and poorly with T2 values of the original tumor. No correlation with T1 values was found. The authors conclude that size of the residual mass can be predicted from the initial size of the tumor and the signal intensity ratios at diagnosis. Since the degree of low signal intensity in the tumor before treatment probably reflects the amount of fibrotic tissue, these results support the hypothesis that residual masses after treatment are remnants of the fibrotic stroma of the original tumor.

Entities:  

Mesh:

Year:  1989        PMID: 2911665     DOI: 10.1148/radiology.170.2.2911665

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

Review 1.  Assessment of response to therapy using conventional imaging.

Authors:  Sheila C Rankin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-27       Impact factor: 9.236

2.  Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study.

Authors:  M Bendini; C Zuiani; M Bazzocchi; G Dalpiaz; F Zaja; E Englaro
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

Review 3.  Oncology imaging: nodal spread-intrathoracic nodes.

Authors:  J A Verschakelen; P de Leyn; J Bogaert; A L Baert
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

4.  Comparison of CT and MRI in the evaluation of therapeutic response in thoracic Hodgkin disease.

Authors:  S S Elkowitz; J C Leonidas; M Lopez; I Cherick; R G Schiff; G Karayalcin; P Lanzkowsky
Journal:  Pediatr Radiol       Date:  1993

5.  Residual mass after treatment of primary cervical lymphoma: the utility of gallium 67 and MRI.

Authors:  C J Kasales; J E Langer; C T Young; K Singapuri; P H Arger
Journal:  Abdom Imaging       Date:  1994 May-Jun

6.  Magnetic resonance imaging for the assessment of residual masses after treatment of non-Hodgkin's lymphomas.

Authors:  C Montalbán; J L Rodríguez-García; L Mazairas; I Ayala; J Marcos-Robles
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

7.  MRI and PET in monitoring response in lymphoma.

Authors:  Alain Rahmouni; Alain Luciani; Emmanuel Itti
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

8.  Lymphoma: a clinical view.

Authors:  M Hill; N Maisey
Journal:  Cancer Imaging       Date:  2000-10-11       Impact factor: 3.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.